Tuesday, December 2, 2014

New York Law Firm Announces That the FDA Has Issued a Warning on the Risks Involved When Taking the Drug Xarelto

This blog title has been optimized using Keyword Winner


(PRWEB) August 12, 2014


Xarelto is an oral anticoagulant drug used to prevent blood clots, and also lowers the risk of stroke in patients who have atrial fibrillation. Xareltos official website 06/17/2014 states, People with atrial fibrillation (an irregular heart beat) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. XARELTO



New York Law Firm Announces That the FDA Has Issued a Warning on the Risks Involved When Taking the Drug Xarelto

Asbestos Scare at U.S. Capitol Highlights Risk Around the Nation, Mesothelioma Law Firm Baron and Budd Reports

This blog title has been optimized using Keyword Winner


DALLAS (PRWEB) August 14, 2014


On July 10, The New York Times published a story stating that a session of the U.S. House of Representatives had to be pushed back due to concerns over the potential risk of exposure to asbestos in a portion of the Capitol Building, the mesothelioma law firm of Baron and Budd reports. Asbestos abatement work was being performed and there was a possible release of the dangerous material. This incident is a reminder that although the use of asbestos has declined substantially in the United States, it still poses a risk because it is found in hundreds of thousands of homes and buildings throughout the nation. And, most importantly, asbestos use is not banned in the U.S. (http://www.nytimes.com/2014/07/11/us/politics/possible-asbestos-risk-at-us-capitol-building.html?emc=edit_cn_20140710&nl=us&nlid=57291641&_r=0)



According to the article, U.S. Capitol Police later issued a statement that normal operations had resumed in the House portion of the Capitol. However, the East Grand staircase and a nearby meeting room would remain closed until the risk of exposure was eliminated. Exposure to asbestos can cause a wide range of health problems, including malignant pleural mesothelioma. This is an aggressive, deadly form of cancer that develops in the lining of the lungs and currently has no cure.



More than likely, if a building was constructed before 1975 it contains asbestos. An estimated 1.2 billion square feet of asbestos insulation still exists in structures throughout the U.S. Asbestos is composed of microscopic fibers that, when disturbed, can break off and become airborne. When these fibers are ingested or inhaled, they can ultimately lead to mesothelioma.



Even though the risks of exposure have been known for years and years, asbestos is, incredibly, still not banned in the United States, said Russell Budd, managing director of mesothelioma law firm Baron and Budd. As long as asbestos is allowed to be used in the U.S., people will continue to develop mesothelioma and suffer terribly as a result.



Please contact the mesothelioma law firm of Baron and Budd if you or someone close to you has been diagnosed with mesothelioma. Call 1-866-855-1229 or visit our mesothelioma-dedicated website at http://www.fightmesothelioma.com to learn about your potential legal options.



ABOUT BARON & BUDD, P.C.



The national mesothelioma law firm of Baron & Budd, P.C. has a more than 30-year history of Protecting Whats Right for asbestos sufferers and their families. As one of the first law firms to successfully litigate an asbestos lawsuit, Baron & Budd continues to actively represent veterans, industry workers and others who are suffering as a result of exposure to asbestos. Baron & Budd achieved the largest mesothelioma verdict ever in the state of Texas, a $ 55 million verdict for an asbestos sufferer and his family in El Paso, Texas. Contact Baron and Budd at 1.866.855.1229 for additional information on mesothelioma treatments, mesothelioma cancer doctors and treatment centers and mesothelioma attorneys.











Asbestos Scare at U.S. Capitol Highlights Risk Around the Nation, Mesothelioma Law Firm Baron and Budd Reports

Perrin Conferences Announces Record Registered Attendance for Asbestos Litigation Conference 2014.

This blog title has been optimized using Keyword Winner


Berwyn, PA (PRWEB) August 15, 2014


Perrin Conferences, acclaimed leader in joint plaintiff/defendant litigation conferences, today announced a record attendance of more than 425 registered participants for its sixth annual Asbestos Litigation Conference: A National Overview & Outlook. The conference will take place September 8-10, 2014, at the Fairmont San Francisco Hotel. With nearly four weeks to go, this year’s attendance is on track to beat last year’s final tally of more than 500 attendees, which was the previous all-time high for the event.


The Asbestos Litigation Conference brings asbestos insurance, legal, corporate and scientific leaders together to consider the direction and climate of current asbestos litigation.



“We are delighted to report continuous year-over-year growth in attendance for the sixth year running,” said Lynnsey Perrin, founder and CEO of Perrin Conferences. “Our numbers reflect the quality of the agenda and the high-caliber industry leaders and speakers participating at the conference. We are excited to create a wonderful experience for each of the Perrin Conference attendees.”



This year’s event will feature breakout sessions and panels covering topics such as:




Perrin Conferences Announces Record Registered Attendance for Asbestos Litigation Conference 2014.

New York Law Firm States That the FDA Announces Health Risks Involved with Patients Who Have Taken Benicar

This blog title has been optimized using Keyword Winner


Commack, New York (PRWEB) August 20, 2014


Benicar is a widely popular drug prescribed to treat hypertension/high blood pressure. Benicars active ingredient is Olmesartan, which in some cases has been shown to injure the blood cells of the small intestine. Olmesartan is also present in Benicar HCT, Tribenzor and Azor. These drugs present the same risk to the small intestine as Benicar. Some users have also experienced a significant decrease in villi, which are cells that help absorb nutrients for the body. As a result, Benicar and its active ingredient have been linked to a plethora of serious health issues including malnutrition, weight loss, dehydration, chronic diarrhea and other serious health effects. Benicar may also cause a rare gastrointestinal illness known as sprue-like enteropathy. The Food and Drug Administration has taken note of these serious conditions that may be related to Benicar. See the Food and Drug Administration Announcement (FDA, 7/3/13).



Rudolph Migliore stated “The FDA has recognized the possible gastrointestinal dangers of this widely prescribed prescription drug. It is of critical importance that doctors and patients are also made aware of how this drug works and that it may have serious side-effects.”



According to Med Page Today (7/3/13), the connection between sprue-like enteropathy and Benicar was first reported by researchers in June 2012. Twenty-two patients from 2008 to 2010 experienced what appeared to be symptoms of celiac disease. However, antibody blood tests and treatments did not support this. The symptoms of sprue-like enteropathy are mirrored by those of Celiac disease, which unlike sprue-like enteropathy is treatable by a gluten-free diet. When the symptoms arise while taking Benicar and persist extensively on a daily basis for an extended period of time, doctors often put the patient on a gluten-free diet to rule out Celiacs disease. However, doctors are finding that some patients dont respond to a gluten-free diet and that these problems are actually caused by Benicar, not Celiacs disease. See the August 2012 report of the Mayo-Clinic which discusses the Benicar connection to Sprue-Like Enteropathy and how it is different from Celiac’s disease.



Symptoms of Sprue-Like Enteropathy include all of those which Benicar users have reported as side effects (malnutrition, weight loss, etc.). The researchers initial patients experienced diarrheal illness for an average of 19 months and were, on average, 69 years old. Discontinuing the drug led to an average weight gain of 27 pounds. See the FDA Announcement (7/3/13).



If you or a loved one has been prescribed Benicar, Benicar HCT, Tribenzor or Azor and is experiencing any of the above side effects, please contact your doctor right away. The Commack, NY law firm of Rudolph F.X. Migliore, P.C. is currently investigating cases involving patients who have been prescribed Benicar and have suffered from severe, chronic diarrhea with substantial weight loss.



About the firm: The law office of Rudolph F. X. Migliore, P. C. has represented clients in a wide range of product liability cases in the last three decades and has worked with nationally recognized associated firms to reach successful verdicts. The Long Island, NY law firm of Rudolph F. X. Migliore, P. C. extends its practice of legal services to medical malpractice, defective medications, defective medical devices, asbestos, mesothelioma, and lung cancer-related cases.











New York Law Firm States That the FDA Announces Health Risks Involved with Patients Who Have Taken Benicar

New York Law Firm States That the FDA Announces Health Risks Involved with Patients Who Have Taken Benicar

This blog title has been optimized using Keyword Winner


Commack, New York (PRWEB) August 20, 2014


Benicar is a widely popular drug prescribed to treat hypertension/high blood pressure. Benicars active ingredient is Olmesartan, which in some cases has been shown to injure the blood cells of the small intestine. Olmesartan is also present in Benicar HCT, Tribenzor and Azor. These drugs present the same risk to the small intestine as Benicar. Some users have also experienced a significant decrease in villi, which are cells that help absorb nutrients for the body. As a result, Benicar and its active ingredient have been linked to a plethora of serious health issues including malnutrition, weight loss, dehydration, chronic diarrhea and other serious health effects. Benicar may also cause a rare gastrointestinal illness known as sprue-like enteropathy. The Food and Drug Administration has taken note of these serious conditions that may be related to Benicar. See the Food and Drug Administration Announcement (FDA, 7/3/13).



Rudolph Migliore stated “The FDA has recognized the possible gastrointestinal dangers of this widely prescribed prescription drug. It is of critical importance that doctors and patients are also made aware of how this drug works and that it may have serious side-effects.”



According to Med Page Today (7/3/13), the connection between sprue-like enteropathy and Benicar was first reported by researchers in June 2012. Twenty-two patients from 2008 to 2010 experienced what appeared to be symptoms of celiac disease. However, antibody blood tests and treatments did not support this. The symptoms of sprue-like enteropathy are mirrored by those of Celiac disease, which unlike sprue-like enteropathy is treatable by a gluten-free diet. When the symptoms arise while taking Benicar and persist extensively on a daily basis for an extended period of time, doctors often put the patient on a gluten-free diet to rule out Celiacs disease. However, doctors are finding that some patients dont respond to a gluten-free diet and that these problems are actually caused by Benicar, not Celiacs disease. See the August 2012 report of the Mayo-Clinic which discusses the Benicar connection to Sprue-Like Enteropathy and how it is different from Celiac’s disease.



Symptoms of Sprue-Like Enteropathy include all of those which Benicar users have reported as side effects (malnutrition, weight loss, etc.). The researchers initial patients experienced diarrheal illness for an average of 19 months and were, on average, 69 years old. Discontinuing the drug led to an average weight gain of 27 pounds. See the FDA Announcement (7/3/13).



If you or a loved one has been prescribed Benicar, Benicar HCT, Tribenzor or Azor and is experiencing any of the above side effects, please contact your doctor right away. The Commack, NY law firm of Rudolph F.X. Migliore, P.C. is currently investigating cases involving patients who have been prescribed Benicar and have suffered from severe, chronic diarrhea with substantial weight loss.



About the firm: The law office of Rudolph F. X. Migliore, P. C. has represented clients in a wide range of product liability cases in the last three decades and has worked with nationally recognized associated firms to reach successful verdicts. The Long Island, NY law firm of Rudolph F. X. Migliore, P. C. extends its practice of legal services to medical malpractice, defective medications, defective medical devices, asbestos, mesothelioma, and lung cancer-related cases.











New York Law Firm States That the FDA Announces Health Risks Involved with Patients Who Have Taken Benicar

$17.7 Million Dollar Verdict for Spouse of Lung Cancer Victim

This blog title has been optimized using Keyword Winner


Los Angeles, CA (PRWEB) August 21, 2014


On July 30, 2014 a jury in Los Angeles County Superior Court returned a verdict in favor of Mrs. Tajie Major, the widow of retired Captain William Major, U.S. Navy, against Lorillard Tobacco Co. for $ 17.736 M (Tajie Major vs. Lorillard Tobacco Co., Case No. BC473650). Plaintiffs counsels, Gil Purcell and Jason Rose of Novato, CA-based Brayton Purcell LLP were understandably pleased with the result for Mrs. Major. Mr. Purcell wished to express his gratitude for the assistance his client received from those who appeared in court during the trial: “We are most appreciative of the witnesses with the courage and resolve to come forward and mete out some justice against [Lorillard Tobacco Co.]” The unanimous 12-0 jury verdict found that Mr. Majors use of Lorillard Tobacco Co.s Kent cigarettes, of Micronite Filter fame, and Newport cigarettes, Lorillard Tobacco Co.s menthol brand, caused his death at the age of 55.



The month-long trial brought an end to the present phase of this case which was filed in 1999 and includes a hiatus of several years in its history (3). As to his client and her persistence over the time that her case has been pending, Mr. Purcell noted Tajie Major is to be commended.



Purcell further commented that in this case “The jury was superb in their commitment to do the right thing based on the evidence and law.” In rendering judgment against Lorillard Tobacco Co., the jury had to confront the plaintiffs argument that a cigarette was not just tobacco rolled in paper, but instead was a highly engineered, mass produced, complex device, as well that all cigarettes were not created equal. The jury also received evidence from the plaintiff that demonstrated that Lorillard Tobacco Co.s Kent and Newport products were meticulously designed to create and sustain an addiction to nicotine (3).



Mrs. Major argued that Lorillard Tobacco Co. expanded vast resources to assess the effects of content manipulation and adulteration not only of tobacco itself and the additives to it, but also of the paper that encased the tobacco and the filters through which smoke was inhaled into the lungs. Ultimately, the jury heard how design changes which could have made significant differences in the health impact and safety of their consumers were ignored by Lorillard Tobacco Co (3).



Through much of this same evidence, the jury unanimously concluded that Mr. Majors lung cancer and death were caused both by the fact that Kent and Newport cigarettes were negligently designed, and that smoking the products created overwhelming and unreasonable risks of harm for the consuming public, like Mr. Major. (2). By their verdict today, the jury unanimously concluded that Kent and Newport cigarettes, made by Lorillard Tobacco Co., failed to meet the California consumer safety based risk-benefit test for design defect.



Unable to assess punitive damages in this wrongful death case, the jury nevertheless found that Mrs. Major had sustained economic loss of $ 2.15M for the financial support her terminally ill husband could no longer provide. Because of his premature death, they also determined she was entitled to recover an additional $ 430,000 in related and other lost benefits, and $ 156,700 for lost household services. Having been married for over 20 years by the time of his death (1), the jury further determined that $ 10M was an appropriate figure to compensate Mrs. Major for the loss of her husband which she had already sustained, and that an additional $ 5M was proper for the future loss she would endure because of Mr. Majors wrongful death. Liability was determined by the jury and Lorillard Tobacco Co. was assessed fault at 17%, while Mr. Major comparative fault was determined to be 50% (3). Other cigarette companies were assessed a 33% share of fault (1) and, despite arguments by Lorillard Tobacco Co. to the contrary, the jury found that possible prior exposure to asbestos played no role in the causation of disease and assigned that agent a 0.0% fault allocation (3).



To prove up Mrs. Majors case, Mr. Purcell and Mr. Rose utilized two noted local physicians: Pulmonologist Barry Horn, M.D. from Alta Bates Hospital in Berkeley, and UC Berkeley Epidemiologist, Alan Smith, M.D. Also testifying in the case was Seattle, WA, pathologist, Samuel P. Hammar, M.D., and one of Mr. Majors treating physicians, Dr. Ronald Miller. These witnesses helped to establish the basic facts of the lung cancer that caused William Majors death. A former Phillip Morris Co. cigarette design engineer, William Farone, PhD., provided testimony which established that design options utilized by cigarette manufacturers, including Lorillard Tobacco Co., exposed users of their products to hundreds of toxic substances and scores of carcinogens, thereby increasing the risks of disease and death to their customers in the process. Such evidence further demonstrated that such risks were avoidable or subject to substantial reduction by known design alternatives, which were ignored by the manufacturers like Lorillard Tobacco Co. Dr. James DiFranza also testified about the addictive properties of nicotine based upon his years of experience in dealing with addicted smokers. James Mills, PhD, an economist, provided the expert testimony upon which the jury relied as the basis to calculate the economic loss Mrs. Major had suffered. Additionally, testimony of numerous witnesses was presented to establish the nature and extent of Mr. Majors use of Lorillard Tobacco Co.s cigarette products.



Assisting the trial team of Gil Purcell and Jason Rose were Brayton Purcell LLP attorney Stephanie Drenski and John Wallace, Of Counsel to the firm.



Opposing Mr. Purcell and Mr. Rose before the Honorable Judge Amy Hogue (LASC,


Dept.: 322) on behalf of Lorillard Tobacco Co., were the St. Louis firm of Thompson Coburn LLP, by Carl L. Rowley and DLA Piper LLP (US) by San Diego partner Brian Foster.



Total verdict: $ 17,736,700.


1) Palos Verdes Estates widow wins lawsuit against cigarette company, Daily Breeze, July 30, 2014, http://www.dailybreeze.com/general-news/20140730/palos-verdes-estates-widow-wins-lawsuit-against-cigarette-company



2) Naval Captains Widow Wins Big Tobacco Verdict, Los Angeles Daily Journal, August 1, 2014, http://www.braytonlaw.com/Firm-Overview/News/Naval-Captains-Widow-Wins-Big-Tobacco-Verdict.shtml (scan of physical document)



3) Lorillard Must Pay $ 4M In Wrongful Death Suit, Jury Says, August 4, 2014, Law360, https://www.law360.com/articles/563977/lorillard-must-pay-4m-in-wrongful-death-suit-jury-says



4) Tajie Major vs. Lorillard Tobacco Co., Case No. BC473650, Case Summary, Los Angeles Superior Court, http://www.lasuperiorcourt.org/civilcasesummarynet/ui/casesummary.aspx











$17.7 Million Dollar Verdict for Spouse of Lung Cancer Victim

Acclaimed Author Lionel Shriver Supports Mesothelioma Awareness Day

This blog title has been optimized using Keyword Winner


Alexandria, VA (PRWEB) August 25, 2014


The Mesothelioma Applied Research Foundation (Meso Foundation) released today a video of award-winning author, Lionel Shriver, in which Ms. Shriver urges viewers to observe September 26th as Mesothelioma Awareness Day. The video can be watched on the Meso Foundations YouTube channel.



Several years ago, one of my closest friends, was diagnosed with mesothelioma, says Ms. Shriver in the video. Her experience of living with the disease, and ultimately dying from it, moved me to write my tenth novel, So Much for That.



So Much for That is a novel that tackles the complicated topic of healthcare in the United States, through the experience of a mesothelioma patient and her family.



In the video, viewers are urged to visit the organizations website, curemeso.org, to learn more about Mesothelioma Awareness Day.



Ms. Shriver is best known as the author of the award-winning novel We Need to Talk About Kevin, and Big Brother.



Mesothelioma Awareness Day is a grassroots movement established in 2004 by volunteers of the Meso Foundation with the goal of bringing more attention and funding to this historically-neglected cancer.



On behalf of the mesothelioma community, I am infinitely grateful to Ms. Shriver for her help in raising awareness, said nurse practitioner and executive director of the Mesothelioma Applied Research Foundation, Mary Hesdorffer.



More awareness of this disease and the consequent increased funding for research, education, support, and advocacy is exactly what is needed to help us save lives, added Ms. Hesdorffer.



Mesothelioma is a malignant tumor of the lining of the lung, abdomen, or heart known to be caused by exposure to asbestos. With the life expectancy of less than one year after diagnosis, medical experts consider it one of the most aggressive and deadly of all cancers. An estimated one-third of those who develop mesothelioma were exposed while serving in the Navy or working in shipyards. Currently, few treatment options exist. There is no cure.



ABOUT THE MESOTHELIOMA APPLIED RESEARCH FOUNDATION


The Meso Foundation is the only 501(c)(3) nonprofit organization dedicated to eradicating mesothelioma and easing the suffering caused by this cancer. The Meso Foundation actively seeks philanthropic support to fund mesothelioma research; provide patient support services and education; and advocate Congress for increased federal funding for mesothelioma research. The Meso Foundation is the only non-government funder of peer-reviewed scientific research to develop life-saving treatments for this extremely aggressive cancer. To date, the Foundation has awarded over $ 8.7 million to research. More information is available at http://www.curemeso.org.



###











Acclaimed Author Lionel Shriver Supports Mesothelioma Awareness Day